Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Incyte Corporation
Dren Bio
AVM Biotechnology Inc
Children's Hospital of Philadelphia
CRISPR Therapeutics
AvenCell Therapeutics, Inc.
Vironexis Biotherapeutics Inc.
City of Hope Medical Center
Syndax Pharmaceuticals
Allogene Therapeutics
University of Chicago
Penn State University
Ossium Health, Inc.
City of Hope Medical Center
Seattle Children's Hospital
Dana-Farber Cancer Institute
Incyte Corporation
Memorial Sloan Kettering Cancer Center
AstraZeneca
Sheba Medical Center
UNC Lineberger Comprehensive Cancer Center
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
St. Jude Children's Research Hospital
Kura Oncology, Inc.
UNC Lineberger Comprehensive Cancer Center
CRISPR Therapeutics
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Biotroy Therapeutics
Princess Maxima Center for Pediatric Oncology
Princess Maxima Center for Pediatric Oncology
Princess Maxima Center for Pediatric Oncology
Princess Maxima Center for Pediatric Oncology
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Seattle Children's Hospital
Jonsson Comprehensive Cancer Center
Princess Maxima Center for Pediatric Oncology
M.D. Anderson Cancer Center
Thomas Jefferson University
Thomas Jefferson University
M.D. Anderson Cancer Center
Takara Bio Inc.
Assiut University
Celgene
Princess Maxima Center for Pediatric Oncology
Kyowa Kirin Co., Ltd.
AO GENERIUM
National Institutes of Health Clinical Center (CC)